Differential expression of two different DOG-1 antibodies: Utility in detecting gastrointestinal stromal tumors

Journal of Histotechnology

Volumn 33, Issue 2, 2010, Pages 71-75

  Schmitt, Alessandra C ^a   Popp, Aimee C ^a   Cohen, Cynthia ^a   Lawson, Diane ^a   Siddiqui, Momin T ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

C kit; DOG 1; Gastrointestinal stromal tumors; K9 and SP31 antibody clones; Protein kinase C theta

Indexed keywords

K9 ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN KINASE C THETA; SP31 ANTIBODY; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ANTIBODY PRODUCTION; ARTICLE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTOCYTOMA; ONCOGENE C KIT; PROTEIN EXPRESSION; SCORING SYSTEM; SEMINOMA; SENSITIVITY AND SPECIFICITY;

EID: 77956090452     PISSN: 01478885     EISSN: None     Source Type: Journal    
DOI: 10.1179/his.2010.33.2.71     Document Type: Article

References (21)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998. (Pubitemid 28221878)
2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002. (Pubitemid 34879334)
3. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al.: KIT-negative gastrointestinal stromal tumors. Proof of concept and therapeutic implications. Am J Surg Pathol 28:889-894, 2004. (Pubitemid 38856844)
4. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al.: A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32:210-218, 2008. (Pubitemid 351172135)
5. Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors. A study of 1840 cases. Am J Surg Pathol 33:1401-1408, 2009.
6. Yantiss RK, Spiro IJ, Compton CC, Rosenberg AE: Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: A clinically important differential diagnosis. Am J Surg Pathol 24:947-957, 2000.
7. Weiss SW, Goldblum JR: Extragastrointestinal Stromal Tumors. Soft Tissue Tumors. 5th ed. Philadelphia, PA: Mosby Elsevier; 2008, pp. 565-581.
8. Altman A, Villalba M: Protein kinase C-theta (PKC theta): It's all about location, location, location. Immunol Rev 192:53-63, 2003. (Pubitemid 36613323)
9. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T: PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 55:106-112, 2005. (Pubitemid 40477221)
10. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, Garcia-Garcia J, et al.: Protein kinase C θ is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10:4089-4095, 2004. (Pubitemid 38812487)
11. Lee HE, Kim MA, Lee HS, Kim WH: Characteristics of Kit-negative gastrointestinal stromal tumors and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol 61:722-729, 2008.
12. Miettinen M, Lasota J: KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinic pathologic correlation. Appl Immunohistochem Mol Morphol 13:205-220, 2005. (Pubitemid 41209013)
13. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al.: The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165:107-113, 2004. (Pubitemid 38821818)
14. Miwa S, Nakajima T, Murai Y, Takano Y, Sugiyama T: Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol 43:531-537, 2008.
15. Liegl B, Hornick JL, Corless CL, Fletcher CD: Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33:437-446, 2009.
16. Dawson B, Trapp RG: Methods of Evidence- Based Medicine & Decision Analysis. Basic & Clinical Biostatistics, 4th edition. New York, NY: Lange Medical Books/McGraw; 2004, pp. 302-331.
17. Montgomery E, Fisher C: Gastrointestinal mesenchymal tumors. In: Goldblum JR, ed. Gastrointestinal and Liver Pathology.1st ed. Philadelphia, PA: Elsevier; 2005, pp. 204-233.
18. Antonescu CR: Targeted therapies in gastrointestinal stromal tumors. Semin Diagn Pathol 25:295-303, 2008.
19. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004.
20. Lasota J, Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors. Histopathology 53:245-266, 2008.
21. Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y, et al.: Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 29:755-763, 2005. (Pubitemid 40734425)